WO1999065523A1 - Immunotherapeutic composition and method for the treatment of prostate cancer - Google Patents
Immunotherapeutic composition and method for the treatment of prostate cancer Download PDFInfo
- Publication number
- WO1999065523A1 WO1999065523A1 PCT/IB1999/001115 IB9901115W WO9965523A1 WO 1999065523 A1 WO1999065523 A1 WO 1999065523A1 IB 9901115 W IB9901115 W IB 9901115W WO 9965523 A1 WO9965523 A1 WO 9965523A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- psa
- antigen
- agent
- bmding
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates generally to the generation of cellular and humoral immune responses to prostate-specific antigen (PSA).
- PSA prostate-specific antigen
- the present invention also relates to a therapeutic composition that contains a monoclonal antibody that is useful in generating cellular and humoral immune responses to PSA.
- Immunogenicity is the property of stimulating the immune system to generate a specific response. Thus, all immunogens are antigens, but not vice-versa. Although an irnmune system may recognize an antigen, it does not respond to the antigen unless the antigen is also immunogenic.
- an antibody whose antigen combining site (paratope) interacts with an antigenic determinant on another antibody V region (idiotope) is called an anti- idiotypic antibody (Ab2).
- an antibody includes an antigen binding site, and may include one or more antibody binding sites.
- anti-idiotypic antibodies sometimes called Ab2 ⁇ and Ab2 ⁇ .
- Ab2 ⁇ anti-idiotype antibody
- the combining site perfecdy mimics the structure of the antigen epitope recognized by the Abl antibody. This type of anti-idiotype is said to represent the internal image of the antigen.
- Administration may be more than once, preferably three times over a prolonged period.
- the compositions of this invention may be used for patient's in a serious disease state, i.e., Ufe-threatening or potentially Ufe-threatening, excesses of the binding agent may be aclministered if desirable.
- Actual methods and protocols for administering pharmaceutical compositions, including dilution techniques for injections of the present compositions, are well known or will be apparent to one skilled in the art. Some of these methods and protocols are described in Remington s Pharmaceutical Science, Mack Publishing Co. (1982).
- Administration may also include ex vivo administration protocols, e.g., removing a portion of a patient's body fluid, contacting in vitro the body fluid with the therapeutic composition, and then returning the treated body fluid to the patient.
- Second screening Hyb ⁇ doma clones secreting anti-PSA antibodies were first detected by ELISA on PSA coated plates (ELISA #1). We selected 80 positive clones from this first screening. Those clones are currently kept frozen m liquid nitrogen tank Second screening: The positive clones were further screened agamst PSA complexed to alpha anti-chymotrypsin (PSA-ACT) (ELISA #2); PSA non complexing to alpha anti- chymotrypsin (ELISA #4); Plasmatique kalhkrem (ELISA #5); and PSA peptide 139-163 (ELISA #6) The reactivity of the AR47 clones towards the different forms of PSA and towards kallikrem is reported in Example 2 The isotype of the antibodies secreted by AR47 clones is reported m Example 3.
- AR 47.47 is directed towards a PSA epitope comprised between the sequence 139-163 of the PSA molecule.
- the anti-PSA antibodies produced by AR 47.47 immunized mice can specifically interact with the PSA peptide 139-163, showing that at least part of the Ab3 produced are identical in term of specificity to AR 47.47.
- Ab2 is a surrogate antigen capable of mimicking the PSA epitope recognized by the injected anti-PSA antibody.
- a competitive inhibition assay was established to measure the serum level of Ab2. This assay was performed 5 days after the second injection. An inhibition was observed after incubation in the presence of mouse sera from mice immunized with anti-PSA antibody, but not when sera from mice immunized with control antibody or PBS were used.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002328504A CA2328504A1 (en) | 1998-06-15 | 1999-06-15 | Immunotherapeutic composition and method for the treatment of prostate cancer |
| EP99925216A EP1085905B1 (en) | 1998-06-15 | 1999-06-15 | Immunotherapeutic composition and method for the treatment of prostate cancer |
| AU41594/99A AU768002B2 (en) | 1998-06-15 | 1999-06-15 | Immunotherapeutic composition and method for the treatment of prostate cancer |
| IL13970099A IL139700A (en) | 1998-06-15 | 1999-06-15 | Immunotherapeutic composition for the treatment of prostate cancer |
| DE69942742T DE69942742D1 (de) | 1998-06-15 | 1999-06-15 | Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs |
| AT99925216T ATE480566T1 (de) | 1998-06-15 | 1999-06-15 | Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs |
| JP2000554401A JP2002518347A (ja) | 1998-06-15 | 1999-06-15 | 前立腺癌治療のための免疫療法組成物および方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8928198P | 1998-06-15 | 1998-06-15 | |
| US60/089,281 | 1998-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999065523A1 true WO1999065523A1 (en) | 1999-12-23 |
Family
ID=22216751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB1999/001115 Ceased WO1999065523A1 (en) | 1998-06-15 | 1999-06-15 | Immunotherapeutic composition and method for the treatment of prostate cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6881405B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1085905B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002518347A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE480566T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU768002B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2328504A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69942742D1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL139700A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999065523A1 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000041722A1 (de) * | 1999-01-13 | 2000-07-20 | Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag | Verwendung von antikörpern zur vakzinierung gegen krebs |
| WO2001085204A3 (en) * | 2000-05-11 | 2002-08-22 | Altarex Inc | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| EP2331130A4 (en) * | 2008-04-09 | 2012-11-07 | Advanced Immune Therapeutics Inc | IGE ANTIBODIES FOR THE TREATMENT OF CANCER |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| ATE480566T1 (de) * | 1998-06-15 | 2010-09-15 | Quest Pharmatech Inc | Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs |
| HRP20041037A2 (en) * | 2002-04-11 | 2005-06-30 | Altarex Medical Corporation | Binding agents and their use in targeting tumor cells |
| EP1578445A4 (en) * | 2002-10-17 | 2007-04-04 | Altarex Medical Corp | THERAPEUTIC ADJUVANS |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| GB0329146D0 (en) * | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| US20080095790A1 (en) * | 2006-10-24 | 2008-04-24 | Perambakam Supriya M | Methods of Treating Prostate Cancer |
| ES2588705T3 (es) * | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| CA2723918C (en) | 2008-06-05 | 2018-01-09 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| GB0811567D0 (en) * | 2008-06-24 | 2008-07-30 | Cytosystems Ltd | Assay |
| PL3912643T3 (pl) | 2009-02-13 | 2023-01-23 | Immunomedics Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
| WO2011034660A1 (en) | 2009-09-16 | 2011-03-24 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| IN2012DN03354A (cg-RX-API-DMAC7.html) | 2009-12-02 | 2015-10-23 | Immunomedics Inc | |
| US9023802B2 (en) * | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| IN2014CN02581A (cg-RX-API-DMAC7.html) | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| ES2978993T3 (es) | 2014-02-21 | 2024-09-23 | Ibc Pharmaceuticals Inc | Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2 |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| PL3204018T3 (pl) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek |
| EP3286224A4 (en) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| PL3316885T3 (pl) | 2015-07-01 | 2021-12-06 | Immunomedics, Inc. | Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a |
| EP4342497A1 (en) | 2021-05-10 | 2024-03-27 | Kawasaki Institute of Industrial Promotion | Antibody having reduced binding affinity for antigen |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0652014A1 (en) * | 1993-11-10 | 1995-05-10 | National Institute Of Immunology | Treatment of prostatic hypertrophy |
| WO1997029199A2 (en) * | 1996-02-06 | 1997-08-14 | Abbott Laboratories | Prostate specific antigen peptides and uses thereof |
| WO1998010292A1 (en) * | 1996-09-06 | 1998-03-12 | Centocor, Inc. | Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3865689A (en) | 1972-11-09 | 1975-02-11 | Hoffmann La Roche | Method of producing carcinoembryonic antigens |
| US4446122A (en) | 1979-12-28 | 1984-05-01 | Research Corporation | Purified human prostate antigen |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US5053224A (en) | 1983-11-07 | 1991-10-01 | Hilary Koprowski | Induction of antibody response to solid tumors with anti-idiotype antibodies |
| DE3650139T2 (de) | 1985-07-05 | 1995-03-09 | Hutchinson Fred Cancer Res | Verfahren zum reduzieren der immunogenizität und zum induzieren immunologischer toleranz. |
| EP0234122A3 (en) | 1986-02-21 | 1989-03-22 | Oncogen Limited Partnership | Tumor therapy with biologically active anti-tumor antibodies |
| AU613590B2 (en) | 1986-11-19 | 1991-08-08 | Bristol-Myers Squibb Company | Hybridomas producing monoclonal antibodies to new mucin epitopes |
| US5059680A (en) | 1986-11-24 | 1991-10-22 | Centocor, Inc. | Method of isolating ca 125 antigen |
| US5683674A (en) | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
| US4859449A (en) | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
| GB8728856D0 (en) | 1987-12-10 | 1988-01-27 | Bradwell A R | Tumour-locating agents & method of locating tumours |
| CA2065874C (en) | 1989-09-15 | 2001-12-11 | Joseph P. Brown | Hybridoma ct43 producing a monoclonal antibody to a mucin epitope of colorectal cancer |
| US5165922A (en) | 1990-05-22 | 1992-11-24 | Bristol-Myers Squibb Company | Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
| DE4133791A1 (de) | 1991-10-11 | 1993-04-15 | Behringwerke Ag | Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung |
| US5773292A (en) | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
| GB9606228D0 (en) | 1996-03-25 | 1996-05-29 | Secr Defence | Apparatus for matrix coating fibres with metal vapour |
| ATE480566T1 (de) * | 1998-06-15 | 2010-09-15 | Quest Pharmatech Inc | Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs |
-
1999
- 1999-06-15 AT AT99925216T patent/ATE480566T1/de not_active IP Right Cessation
- 1999-06-15 AU AU41594/99A patent/AU768002B2/en not_active Ceased
- 1999-06-15 CA CA002328504A patent/CA2328504A1/en not_active Abandoned
- 1999-06-15 US US09/332,866 patent/US6881405B2/en not_active Expired - Lifetime
- 1999-06-15 EP EP99925216A patent/EP1085905B1/en not_active Expired - Lifetime
- 1999-06-15 DE DE69942742T patent/DE69942742D1/de not_active Expired - Lifetime
- 1999-06-15 JP JP2000554401A patent/JP2002518347A/ja active Pending
- 1999-06-15 WO PCT/IB1999/001115 patent/WO1999065523A1/en not_active Ceased
- 1999-06-15 IL IL13970099A patent/IL139700A/xx not_active IP Right Cessation
-
2004
- 2004-10-14 US US10/966,789 patent/US7579445B2/en not_active Expired - Fee Related
-
2007
- 2007-10-31 US US11/981,715 patent/US20090220493A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0652014A1 (en) * | 1993-11-10 | 1995-05-10 | National Institute Of Immunology | Treatment of prostatic hypertrophy |
| WO1997029199A2 (en) * | 1996-02-06 | 1997-08-14 | Abbott Laboratories | Prostate specific antigen peptides and uses thereof |
| WO1998010292A1 (en) * | 1996-09-06 | 1998-03-12 | Centocor, Inc. | Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen |
Non-Patent Citations (3)
| Title |
|---|
| CORREALE P ET AL: "In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 89, no. 4, 19 February 1997 (1997-02-19), pages 293 - 300, XP002039189 * |
| LEVEUGLE B ET AL: "PSA-directed immunotherapy of prostate cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 39, March 1998 (1998-03-01), pages 355, XP002117652 * |
| UEMURA H ET AL: "Generation of anti-idiotype antibodies related to PSA: posible tools for treatment of prostate cancer.", JOURNAL OF UROLOGY, vol. 153, no. SUPPL 4, 1995, pages 380A, XP002117650 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000041722A1 (de) * | 1999-01-13 | 2000-07-20 | Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag | Verwendung von antikörpern zur vakzinierung gegen krebs |
| EP1230932A3 (de) * | 1999-01-13 | 2003-11-26 | Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG | Verwendung von Antikörpern zur Vakzinierung gegen Krebs |
| US7691372B2 (en) | 1999-01-13 | 2010-04-06 | Igeneon Krebs-Immuntherapie Forschungs-und Entwickungs-AG | Use of antibodies for the vaccination against cancer |
| US8444974B2 (en) | 1999-01-13 | 2013-05-21 | Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag | Use of antibodies for the vaccination against cancer |
| WO2001085204A3 (en) * | 2000-05-11 | 2002-08-22 | Altarex Inc | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| WO2001085203A3 (en) * | 2000-05-11 | 2002-08-22 | Altarex Inc | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| US6689355B2 (en) | 2000-05-11 | 2004-02-10 | Altarex Corp. | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| EP2331130A4 (en) * | 2008-04-09 | 2012-11-07 | Advanced Immune Therapeutics Inc | IGE ANTIBODIES FOR THE TREATMENT OF CANCER |
| US8697079B2 (en) | 2008-04-09 | 2014-04-15 | Quest Pharma Tech Inc. | IgE antibodies for the treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1085905A1 (en) | 2001-03-28 |
| US6881405B2 (en) | 2005-04-19 |
| AU4159499A (en) | 2000-01-05 |
| US20050202018A1 (en) | 2005-09-15 |
| US7579445B2 (en) | 2009-08-25 |
| CA2328504A1 (en) | 1999-12-23 |
| DE69942742D1 (de) | 2010-10-21 |
| JP2002518347A (ja) | 2002-06-25 |
| ATE480566T1 (de) | 2010-09-15 |
| IL139700A0 (en) | 2002-02-10 |
| IL139700A (en) | 2005-09-25 |
| AU768002B2 (en) | 2003-11-27 |
| US20020136715A1 (en) | 2002-09-26 |
| EP1085905B1 (en) | 2010-09-08 |
| US20090220493A1 (en) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7579445B2 (en) | Reagents and methods for inducing an immune response to prostate specific antigen | |
| US20080131443A1 (en) | Method and composition for reconforming multi-epitopic antigens to intiate an immune response | |
| JPH09504000A (ja) | 前立腺癌ワクチン | |
| JPH11515005A (ja) | 抗原提示細胞により仲介される免疫応答を高めるための組成物および方法 | |
| CA2360382C (en) | Use of antibodies for the vaccination against cancer | |
| Verch et al. | Immunization with a plant-produced colorectal cancer antigen | |
| AU762699B2 (en) | Therapeutic compositions that produce an immune response by altering the antigen | |
| US20090202560A1 (en) | Method for diagnosing efficacy of xenotypic antibody therapy | |
| CA2253058A1 (en) | Therapeutic composition that produce and immune response | |
| US7361346B1 (en) | Therapeutic compositions that produce an immune response | |
| Ma et al. | Characterization and evaluation of a novel anti-MUC-1 monoclonal antibody: induction of the idiotypic network in experimental mice | |
| KR100372958B1 (ko) | 면역반응을개시시키기위해다중에피토프항원의입체형태를변화시키기위한방법및조성물 | |
| NZ503032A (en) | Use of a binding agent to reconforming multi-epitopic antigens to initiate an immune response | |
| MXPA98009586A (en) | Method and composition for the reconformation of multi-peptide antigens to start an animal response |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| ENP | Entry into the national phase |
Ref document number: 2328504 Country of ref document: CA Ref country code: CA Ref document number: 2328504 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 139700 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 41594/99 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1999925216 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999925216 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 41594/99 Country of ref document: AU |